Syncom Formulations (India) Ltd

Syncom Formul. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Syncom Formulations (India) Ltd

₹ 15.6 -2.50%
27 May - close price
syncomformulations.com BSE: 524470 NSE: SYNCOMF
About

Established in the year 1995, Syncom Formulations is a global pharmaceutical company that manufactures and markets a broad range of healthcare products. The company is a generic pharmaceutical player operating in more than 15 countries worldwide having more than 400 products registered.[1]

Key Points

Business Overview
The company manufactures and markets 500+ pharmaceutical formulations products in various dosage forms like Tablets, Capsules, Liquids Orals, Liquid Vials and Ampoule Injections & Dry Vial injections, Dry Syrups, Ointments and Inhalers. It is also involved in trading commodities and rental of properties. [1]

Website BSE NSE
  • Market Cap ₹ 1,466 Cr.
  • Current Price ₹ 15.6
  • High / Low ₹ 22.8 / 10.2
  • Stock P/E 19.2
  • Book Value ₹ 4.41
  • Dividend Yield 0.00 %
  • ROCE 26.8 %
  • ROE 20.2 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Debtor days have improved from 104 to 82.4 days.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Earnings include an other income of Rs.31.4 Cr.
  • Working capital days have increased from 104 days to 164 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
61 60 64 65 75 87 102 128 149 117 122 115 135
55 53 57 58 65 77 90 113 131 101 103 94 113
Operating Profit 6 6 6 7 9 10 12 15 18 16 18 21 22
OPM % 10% 11% 10% 11% 13% 12% 12% 12% 12% 14% 15% 18% 16%
7 2 4 5 3 1 4 4 7 6 5 6 15
Interest 1 1 1 1 1 0 0 0 0 0 0 0 0
Depreciation 1 1 1 1 1 1 1 1 1 1 1 1 2
Profit before tax 10 6 8 9 10 10 15 17 23 20 22 25 34
Tax % 18% 28% 23% 25% 26% 24% 25% 25% 24% 22% 25% 25% 25%
8 4 7 7 7 8 11 13 18 16 17 19 25
EPS in Rs 0.09 0.05 0.07 0.07 0.08 0.08 0.12 0.14 0.19 0.17 0.18 0.20 0.27
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
115 151 173 184 185 216 222 262 463 489
104 135 155 167 168 196 202 232 408 412
Operating Profit 11 16 18 17 17 20 20 30 54 77
OPM % 9% 11% 11% 9% 9% 9% 9% 11% 12% 16%
1 1 1 3 3 12 15 14 17 31
Interest 1 0 0 0 0 2 3 5 1 1
Depreciation 3 3 3 3 3 4 5 5 5 7
Profit before tax 8 14 16 16 16 26 27 34 66 101
Tax % 33% 33% 38% 36% 34% 24% 24% 25% 25% 24%
6 9 10 10 11 20 20 25 49 76
EPS in Rs 0.07 0.12 0.13 0.13 0.13 0.23 0.21 0.27 0.53 0.81
Dividend Payout % 24% 17% 16% 15% 15% 13% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 10%
5 Years: %
3 Years: 30%
TTM: 6%
Compounded Profit Growth
10 Years: 22%
5 Years: %
3 Years: 57%
TTM: 56%
Stock Price CAGR
10 Years: 21%
5 Years: 16%
3 Years: 30%
1 Year: -28%
Return on Equity
10 Years: %
5 Years: 13%
3 Years: 16%
Last Year: 20%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 22 78 78 78 78 86 94 94 94 94
Reserves 65 17 22 31 39 136 162 194 248 321
2 3 6 6 12 58 83 72 5 1
33 42 31 61 50 28 39 44 67 117
Total Liabilities 123 140 138 175 180 308 378 405 413 534
50 50 46 46 55 94 91 120 125 184
CWIP 0 0 0 5 0 6 26 0 0 0
Investments 7 9 6 23 36 43 64 66 93 109
66 80 85 101 89 165 197 219 196 241
Total Assets 123 140 138 175 180 308 378 405 413 534

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
6 7 0 24 14 16 11 -6 23 58
-0 -4 1 -23 -18 -27 -45 83 -18 -51
-6 -1 1 -2 5 8 35 -15 -68 -3
Net Cash Flow -1 2 2 -1 1 -2 1 62 -63 4
Free Cash Flow 3 4 -3 21 2 5 -10 -14 13 46
CFO/OP 76% 66% 32% 176% 108% 113% 86% 7% 70% 105%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 92 71 66 91 91 114 124 144 85 82
Inventory Days 29 36 34 43 29 51 55 49 49 81
Days Payable 91 105 63 130 92 36 53 56 51 96
Cash Conversion Cycle 29 1 37 4 27 129 126 137 83 68
Working Capital Days 94 75 85 40 42 33 -4 51 95 164
ROCE % 15% 16% 15% 13% 10% 11% 19% 27%

Insights

In beta
Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Total Permanent Employees
Number ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Number of SKUs (Pharmaceutical Formulations)
Number ・Standalone data
Solar Power Generation
Lakh Units ・Standalone data
Export Presence (Countries Served)
Count ・Standalone data
Total Energy Consumed
Units ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57% 50.57%
0.00% 0.00% 0.00% 0.08% 0.09% 0.10% 0.13% 0.11% 0.41% 0.10% 0.26% 0.21%
49.44% 49.44% 49.44% 49.35% 49.34% 49.34% 49.30% 49.32% 49.02% 49.33% 49.17% 49.23%
No. of Shareholders 2,24,9252,24,2522,89,9823,25,7613,76,5304,69,2424,89,5204,84,5294,71,0664,57,3644,42,2804,31,690

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Right Issue